Bill
SB 568
SB 568 creates a temporary NC task force to study psychedelic medicines for mental health and advise on licensing, coverage, and policy; final report due Dec 1, 2026.
Status & timing
- Bill number: SB 568
- Title: Innovative Treatments for Mental Health Act
- Introduced: (per your file) February 20, 2025
- Current status: Passed 1st reading (bill text provided)
- Effective date: the act takes effect when enacted into law (per bill)
Purpose / intent
- Authorizes the Department of Health and Human Services (DHHS), Division of Mental Health, Developmental Disabilities, and Substance Use Services, to establish a temporary “North Carolina Mental Health and Psychedelic Medicine Task Force.”
- The Task Force’s purpose is to study the potential role of psychedelic medicines in responding to the State’s mental health needs and to recommend policy, regulatory, licensing, and insurance frameworks if those medicines become federally reclassified and FDA‑approved.
Key provisions
- Authorization: DHHS “may” establish the Task Force (creation is permissive, not mandatory).
- Core study topics:
- Assess clinical potential and applicability of psychedelic medicine for mental health.
- Identify barriers to implementation and equitable access.
- Consider and recommend practitioner licensing standards and insurance coverage requirements in the event of federal reclassification/FDA approval.
- Explore legal and regulatory pathways to state legalization (if applicable) and the public‑health implications of such changes.
- Membership (multi‑stakeholder composition):
- Executive designees: Secretary of DHHS, Secretary of Military and Veterans Affairs, Secretary of Commerce (or each Secretary’s designee).
- Selected representatives: a mental‑health advocacy org, tribal health representative (Eastern Band of Cherokee Indians), survivor‑advocacy (domestic/sexual‑assault), psychiatric profession (NC Psychiatric Association).
- Academic representation: one faculty member each from UNC School of Medicine and ECU Brody School of Medicine (selected by the respective deans).
- Legislative members: two Senators (appointed by Senate leaders) and two House members (appointed by House leaders).
- Up to three additional members selected by the Task Force (examples: veterans groups, first responders, anti‑trafficking, law‑enforcement, victims’ rights).
- Organization and operations:
- The Task Force elects its chair; vacancies are filled as originally appointed.
- Members eligible for per diem, subsistence, and travel allowances under existing statute (G.S. 120‑3.1; 138‑5; 138‑6).
- Required to meet at least four times and be available for legislative hearings.
- Deliverable and sunset:
- Final report, including any proposed legislation, due to the General Assembly by December 1, 2026.
- The Task Force terminates December 31, 2026, or upon filing the final report — whichever is later.
Who would be affected
- State agencies: DHHS (responsible for standing up and supporting the Task Force if it proceeds); potential engagement from Departments of Military & Veterans Affairs and Commerce.
- Health care stakeholders: psychiatrists, medical schools, mental‑health advocacy organizations, survivor‑advocacy groups, tribal health leadership, veterans/first‑responder organizations.
- Legislators: receive Task Force findings and possible recommended bills.
- General public: no immediate change to drug policy or clinical practice; the bill only establishes a study/advisory body to inform potential future action.
Anticipated impacts and considerations
- Short term: administrative costs and staff time for DHHS to convene and support the Task Force; modest costs for member travel/per diem. No direct change to clinical practice, licensure, or insurance rules at enactment.
- Medium term: report may propose statutory or regulatory changes (licensing, reimbursement, access safeguards) that could lead to subsequent legislation if psychedelics are federally reclassified or FDA‑approved.
- Policy considerations likely to be addressed by the Task Force: equity of access, practitioner training and scope, safety and risk‑management, interactions with criminal law and controlled‑substance frameworks, and protections for vulnerable populations.
Procedural / timeline highlights
- Task Force must meet at least four times.
- Final report due to the General Assembly by December 1, 2026.
- Task Force terminates December 31, 2026 (or upon report filing).
Bottom line
SB 568 does not legalize or regulate psychedelic medicines directly. It creates (authorizes) a multi‑stakeholder, time‑limited Task Force to study clinical, regulatory, licensing, insurance, equity, and public‑health issues related to psychedelic medicine, and to submit findings — including proposed legislation — to the General Assembly by December 1, 2026.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
